Post-polycythemia vera related myelofibrosis

Clinical trials for Post-polycythemia vera related myelofibrosis explained in plain language.

Never miss a new study

Get alerted when new Post-polycythemia vera related myelofibrosis trials appear

Sign up with your email to follow new studies for Post-polycythemia vera related myelofibrosis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Can an arthritis drug tame a rare bone marrow cancer?

Disease control Ongoing

This phase 2 trial tests canakinumab, an anti-inflammatory drug, in 14 to 26 people with myelofibrosis, a rare bone marrow cancer that causes scarring, enlarged spleen, and fatigue. Participants receive injections every three weeks for about six months. The study checks if the dr…

Matched conditions: POST-POLYCYTHEMIA VERA RELATED MYELOFIBROSIS

Phase 2 • Sponsor: John Mascarenhas • Aim: Disease control

Last updated Jun 27, 2026 12:31 UTC

Post-polycythemia vera related myelofibrosis

Get alerted when new Post-polycythemia vera related myelofibrosis trials appear

Can an arthritis drug tame a rare bone marrow cancer?